New York, New York (PRWEB) November 24, 2013
As Risperdal lawsuit claims alleging an association between use of the antipsychotic drug and gynecomastia, or male breast growth, continue to move forward in courts throughout the country, Bernstein Liebhard LLP announces that it has launched a new Risperdal lawsuit website (http://www.risperdallawsuitcenter.com) The new website will provide patients and their families with the most updated information regarding the ongoing litigation of product liability claims involving Risperdal and gynecomastia.
“In light of the ongoing Risperdal litigation, as well as news of a recent settlement involving the drug between Johnson & Johnson and the federal government, our Firm felt it was important to take further steps to provide the public with convenient access to the most up-to-date information on this important issue,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to their use of the drug.
Risperdal and Gynecomastia
Risperdal is an antipsychotic medication that has been on the market since 1993, and is used to treat a number of psychiatric ailments in adults and children. According to court documents, at least 250 Risperdal lawsuits are currently pending in a consolidated litigation underway in the Philadelphia Court of Common Pleas in Pennsylvania, all of which were filed on behalf of individuals who were allegedly harmed by the drug. A number of these claims involve allegations of a link between Risperdal and gynecomastia. (Risperdal Litigation, case number 100300296)
On November 4th, the U.S. Department of Justice (DOJ) announced that Johnson & Johnson had agreed to pay $2.2 million to resolve criminal and civil claims involving the improper marketing of Risperdal and other drugs. Among other things, the Justice Department had alleged that Johnson & Johnson marketed Risperdal for pediatric uses long before the U.S. Food & Drug Administration (FDA) approved such indications in 2006. Federal prosecutors also charged that the company knew that Risperdal posed serious risks to children, including an association with male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Individuals who may have been harmed by Risperdal could be entitled to compensationfor their injuries. To learn more about the alleged connection between Risperdal and Gynecomastia, please visit Bernstein Liebhard LLP’s website. For a free, no-obligation review of a potential Risperdal lawsuit, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb11363887.htm.
Copyright©2012 Vocus, Inc.
All rights reserved